Shenzhen Salubris Pharmaceuticals

002294.SZPhase 3

Shenzhen, ChinaFounded 1998salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a leading Chinese pharmaceutical company that develops, manufactures, and commercializes pharmaceutical products and medical devices. The company has built a diversified portfolio spanning multiple therapeutic areas with a focus on high-quality generic drugs and innovative pharmaceutical solutions. Listed on the Shenzhen Stock Exchange, Salubris has established itself as a significant player in China's pharmaceutical market with strong manufacturing capabilities and expanding R&D operations.

Market Cap

$9.4B

Founded

1998

Focus

Biotech

002294.SZ · Stock Price

USD 58.10+34.59 (+147.13%)

Historical price data

AI Company Overview

Technology Platform

Comprehensive pharmaceutical manufacturing and development platform with capabilities in small molecule drugs, various dosage forms, and medical devices, supported by GMP-compliant manufacturing facilities.

Pipeline Snapshot

26 drugs in pipeline, 11 in Phase 3

Drug	Indication	Stage
Enarodustat 2mg + Enarodustat 3mg + Enarodustat 4mg	Renal Anemia in Non-dialysis Chronic Kidney Disease	Approved
Clopidogrel	Coronary Heart Disease	Approved
Allisartan Isoproxil Tablets 240mg or placebo + Allisartan Isoproxil Tablets 480...	Healthy Participants	Approved
SAL067 + Alogliptin + Placebo	Diabetes Mellitus, Type 2	Phase 3
Bivalirudin + heparin	Acute Myocardial Infarction	Phase 3

Opportunities

Strong growth potential in China's expanding pharmaceutical market, opportunities for portfolio expansion across multiple therapeutic areas, and potential for international market expansion leveraging established manufacturing capabilities.

Risk Factors

Intense competition in generic drug markets, regulatory changes in Chinese healthcare policies, pricing pressures from government reforms, and quality control challenges in pharmaceutical manufacturing.

Competitive Landscape

Operates in a highly competitive market against both domestic Chinese pharmaceutical companies and multinational corporations, differentiated by manufacturing excellence, cost-effective development, and established distribution networks in China.

Publications

Patents

Pipeline